Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Children's Oncology Group
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. To identify novel recurrent de novo germline mutations among rhabdomyosarcoma (RMS) case-parent trios.
II. To identify the frequency of de novo germline mutations in cancer predisposition genes among RMS case-parent trios.
SECONDARY OBJECTIVES:
I. To conduct ?deep phenotyping? of children diagnosed with RMS utilizing questionnaire data and information from medical records.
OUTLINE:
Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline deoxyribonucleic acid (DNA) from saliva or buccal mucosa is evaluated via whole exome sequencing.
Age
0–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient must be enrolled on ACCRN07 and/or APEC14B1 and registered with COG by a North American member institution
The patient must have a diagnosis of embryonal rhabdomyosarcoma or alveolar rhabdomyosarcoma
The patient must be diagnosed with rhabdomyosarcoma between January 1, 2012 and November 30, 2019
Concomitant treatment on a therapeutic trial is not required
The patient must have at least one biological parent alive and willing to participate
All questionnaire respondents must understand English or Spanish
All patients and/or their parents or legal guardians must sign a written informed consent
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Clareo Health | Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma
